← Top stories
Market move▲ Bullish for Zydus Lifesciences
Zydus hits 52-week high, can the optimism continue?
The brief
- Zydus Lifesciences has gained 32% in 2026
- Favourable US FDA inspections, resilient India growth and a strong pipeline supported gains
- Resilient domestic growth supports Zydus Lifesciences; US weakness and margins remain risks
- Trade Spotlight: How should you trade LIC Housing Finance, IREDA, Mahindra and Mahindra, Swiggy, Zydus Lifesciences, SAIL, and others on September 29?
- Top stocks to watch today: Why IRFC, Ola, NCC, Tata stocks must be on radar? Full list for Tuesday, 29 September
- Five Stocks To Buy Today, Sept 29: Kaynes Technology, Aegis Vopak Terminals, Zydus Lifesciences, And More
- Zydus Lifesciences gains 2%, hits 52-week high in weak market; here's why
- Buzzing Stocks: Prestige Estates falls as subsidiary withdraws DRHP; Zydus Life hits 52-week high on zero observations
Zydus Lifesciences USFDA inspections
Zydus’s New Jersey office cleared a USFDA inspection with no observations; its Ahmedabad plant inspection concluded with one observation and no data-integrity-related findings. The company said it would work closely with the regulator.
Tuesday, 29 September
- Zydus hits 52-week high, can the optimism continue?